Current treatments for renal failure due to multiple myeloma

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2013-07-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14656566.2016.1236915PMID 27646819
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pre-ESRD Care and Mortality in Incident ESRD Patients With Multiple Myeloma

  2016cited by this paper
• A practical review on carfilzomib in multiple myeloma

  2016cited by this paper
• Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

  2016cited by this paper
• Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis

  2016influential reference
• Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.

  2016cited by this paper
• Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

  2016cited by this paper
• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

  2016cited by this paper
• Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma.

  2016cited by this paper
• International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

  2016influential reference
• Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

  2015cited by this paper
• Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment

  2015cited by this paper
• Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

  2015cited by this paper
• Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

  2015cited by this paper
• Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study

  2015cited by this paper
• Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

  2015cited by this paper
• Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients.

  2015influential reference
• Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis

  2015cited by this paper
• Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

  2015cited by this paper
• European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

  2015cited by this paper
• Safety of Treatment (Tx) with Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI), Including Those on Dialysis

  2015cited by this paper
• Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors.

  2015cited by this paper
• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

  2015cited by this paper
• Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

  2015influential reference
• Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

  2014cited by this paper
• Cardiac metastasis in Merkel cell carcinoma.

  2014cited by this paper
• Application of RIFLE criteria in patients with multiple myeloma with acute kidney injury: a 15-year retrospective, single center, cohort study

  2014cited by this paper
• Myeloma-related kidney disease.

  2014influential reference
• The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment

  2014cited by this paper
• Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010)

  2014cited by this paper
• MM-013: An ongoing phase 2 trial of pomalidomide and low-dose dexamethasone (POM + LoDEX) in relapsed/refractory multiple myeloma (RRMM) with moderate or severe renal impairment (RI) including patients (pts) undergoing hemodialysis.

  2014cited by this paper
• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

  2014cited by this paper
• Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

  2014cited by this paper
• Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

  2014cited by this paper
• Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial

  2014cited by this paper
• Bortezomib improves outcome after SCT in multiple myeloma patients with end-stage renal failure

  2014cited by this paper
• Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.

  2014cited by this paper
• International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.

  2013cited by this paper
• Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.

  2013cited by this paper
• Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

  2013cited by this paper
• The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma

  2013influential reference
• Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): MM-003 analysis of patients (pts) with moderate renal impairment (RI).

  2013cited by this paper
• The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD‐EPI‐CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD‐EPI‐CysC equations?

  2013cited by this paper
• Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

  2013cited by this paper
• Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?

  2013cited by this paper
• Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT

  2013cited by this paper
• Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions

  2013cited by this paper
• Current treatments for renal failure due to multiple myeloma

  2013influential reference
• Efficacy of urine alkalinization by oral administration of sodium bicarbonate: a prospective open-label trial.

  2013cited by this paper
• Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Impact of Renal Function on Patient Outcomes

  2012cited by this paper
• Tubular Damage Is Ubiquitous in Newly-Diagnosed Patients with Multiple Myeloma: Comparison of Three Urinary and Two Serum Markers of Kidney Injury.

  2012cited by this paper
• Estimating glomerular filtration rate from serum creatinine and cystatin C.

  2012cited by this paper
• Defining the Role of Renal Transplantation in the Modern Management of Multiple Myeloma and Other Plasma Cell Dyscrasias

  2012cited by this paper
• Novel approaches for reducing free light chains in patients with myeloma kidney

  2012influential reference
• The pathogenesis and diagnosis of acute kidney injury in multiple myeloma

  2012cited by this paper
• Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.

  2012cited by this paper
• Bisphosphonates in multiple myeloma: a network meta-analysis.

  2012cited by this paper
• An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

  2012cited by this paper
• Significant Improvement of the Survival of Patients with Multiple Myeloma Presenting with Severe Renal Impairment After the Introduction of Novel Agents

  2012cited by this paper
• Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

  2012cited by this paper
• A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

  2012cited by this paper
• Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution.

  2012cited by this paper
• Differential diagnosis of monoclonal gammopathy of undetermined significance.

  2012cited by this paper
• Pomalidomide in Combination with Low-Dose Dexamethasone: Demonstrates a Significant Progression Free Survival and Overall Survival Advantage, in Relapsed/Refractory MM: A Phase 3, Multicenter, Randomized, Open-Label Study

  2012cited by this paper
• Absorption, metabolism and excretion of [14C]pomalidomide in humans following oral administration

  2012cited by this paper
• Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies.

  2012cited by this paper
• Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.

  2012influential reference
• Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens

  2011cited by this paper
• Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment

  2011cited by this paper
• Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

  2011cited by this paper
• The biology of immunoglobulin free light chains and kidney injury.

  2011cited by this paper
• Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.

  2011influential reference
• Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment.

  2011cited by this paper
• Renal improvement in myeloma with bortezomib plus plasma exchange.

  2011influential reference
• Long-Term Follow-Up of Recipients of Combined Human Leukocyte Antigen-Matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With End-Stage Renal Disease

  2011cited by this paper
• Immunoglobulin light chains activate nuclear factor-κB in renal epithelial cells through a Src-dependent mechanism.

  2011cited by this paper
• Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis.

  2011cited by this paper
• Outcome definitions in non-dialysis intervention and prevention trials in acute kidney injury (AKI).

  2010cited by this paper
• Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre.

  2010cited by this paper
• Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

  2010cited by this paper
• Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

  2010cited by this paper
• Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study

  2010cited by this paper
• Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment

  2010cited by this paper
• Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years

  2010cited by this paper
• Safety and efficacy of bortezomib‐based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA

  2010cited by this paper
• The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function.

  2010cited by this paper
• A comparative assessment of the RIFLE, AKIN and conventional criteria for acute kidney injury after hematopoietic SCT

  2010cited by this paper
• The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function

  2010cited by this paper
• Meeting the Unmet Needs in Anticoagulant Therapy

  2010cited by this paper
• Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.

  2010influential reference
• Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

  2010cited by this paper
• Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.

  2010cited by this paper
• Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.

  2010cited by this paper
• Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry study.

  2010cited by this paper
• VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

  2009cited by this paper
• Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis.

  2009cited by this paper
• Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

  2009cited by this paper
• Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.

  2009cited by this paper
• The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.

  2009cited by this paper
• Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma.

  2009cited by this paper
• Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.

  2009cited by this paper

• Demographic and regional trends in all-cause mortality among adults with coexisting multiple myeloma and cardiovascular disease in the United States, 1999-2023: A CDC WONDER analysis.

  2026cites this paper
• Evaluation of current survival and prognostic factors in multiple myeloma: Staging ISS or R-ISS?

  2025cites this paper
• Renal Failure Due to Multiple Myeloma

  2025cites this paper
• Clinicopathologic predictors of renal response and survival in newly diagnosed multiple myeloma with renal injury: a retrospective study

  2025cites this paper
• Treatment outcomes in patients with newly diagnosed multiple myeloma complicated by severe renal failure requiring hemodialysis

  2024cites this paper
• One Case of Acute Kidney Failure Caused by Multiple Myeloma and Literature Review

  2023cites this paper
• Impact of dialysis dependence on survival for multiple myeloma with renal impairment: a multicenter study in China.

  2023cites this paper
• Low non‐relapse mortality and good haematological and renal responses after autologous haematopoietic stem cell transplantation in multiple myeloma patients with renal insufficiency at transplant: A prospective Société Francophone de Greffe de Moelle‐Thérapie Cellulaire observational study

  2023cites this paper
• Cardiovascular-specific mortality among multiple myeloma patients: a population-based study

  2022cites this paper
• What’s Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma

  2022cites this paper
• Role of prognostic scores in the evolution of renal involvement in patients with multiple myeloma after bone marrow transplantation

  2022cites this paper
• RENAL FAILURE IN MULTIPLE MYELOMA: THE ROLE OF PLASMAPHERESIS AND CHEMOTHERAPY ON REVERSIBILITY AND PROGNOSIS - A SINGLE CENTER EXPERIENCE FROM INDIA

  2022influential citation
• Monoclonal Immunoglobulin-Associated Renal Lesions in Patients with Newly Diagnosed Multiple Myeloma: A Report from a Single Center

  2021cites this paper
• Biochemical profile of multiple myeloma about 50 cases

  2021cites this paper
• EVALUATION OF IMPROVEMENT IN RENAL FUNCTION AFTER FIRST-LINE CHEMOTHERAPY IN MULTIPLE MYELOMA PATIENTS PRESENTING WITH RENAL IMPAIRMENT

  2021cites this paper
• CMAR_A_301818 3879..3888

  2021cites this paper
• Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

  2020cites this paper
• Potential of microRNA expression profile in predicting renal impairment risk in multiple myeloma patients

  2020cites this paper
• Evidence-based recommendations for the management of symptoms and care for patients with multiple myeloma

  2020cites this paper
• PDTC inhibits apoptosis and phenotypic transformation of co-culture of myeloma cells and renal tubular epithelial cells by reducing the secretion of light chain protein

  2020cites this paper
• Pyrrolidinedithiocarbamic Acid Ammonium Salt Inhibits Apoptosis and Phenotypic Transformation of Co-Culture of Myeloma Cells and Renal Tubular Epithelial Cells by Reducing the Secretion of Light Chain Protein

  2020cites this paper
• Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis.

  2020cites this paper
• Management of Newly Diagnosed Elderly Multiple Myeloma Patients

  2019cites this paper
• Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe?

  2019cites this paper
• КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ ВОССТАНОВЛЕНИЯ ФУНКЦИИ ПОЧЕК У БОЛЬНЫХ ВПЕРВЫЕ ДИАГНОСТИРОВАННОЙ МНОЖЕСТВЕННОЙ МИЕЛОМОЙ, ОСЛОЖНЕННОЙ ТЯЖЕЛОЙ И ДИАЛИЗ-ЗАВИСИМОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ

  2019cites this paper
• CMAR_A_218979 8295..8302

  2019cites this paper
• CLINICAL IMPORTANCE OF RENAL RECOVER ON OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH SEVERE AND DIALYSIS-DEPENDENT KIDNEY FAILURE

  2019cites this paper
• Understanding mortality in multiple myeloma: Findings of a European retrospective chart review

  2019cites this paper
• Analysis of the efficacy and safety of bortezomib for treating newly diagnosed multiple myeloma through different administration methods

  2019cites this paper
• THE FREQUENCY OF SEVERITY OF ACUTE KIDNEY INJURY IN ASPHYXIA NEOTORUM

  2018cites this paper
• Heavy-Chain Diseases and Myeloma-Associated Fanconi Syndrome: an Update

  2018cites this paper
• Management of multiple myeloma bone disease: impact of treatment on renal function

  2018cites this paper
• The power of proteasome inhibition in multiple myeloma

  2018cites this paper
• Treatment of Elderly Patients with Multiple Myeloma

  2018cites this paper
• Other Complications of Multiple Myeloma

  2018cites this paper
• Hematopoietic Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Therapies

  2018cites this paper
• A population‐based study of the impact of dialysis on mortality in multiple myeloma

  2018cites this paper
• Cure of Insulin-Dependent Diabetes Mellitusby an Autologous Hematopoietic StemCell Transplantation Performed to ControlMultiple Myeloma in a Patient with ChronicRenal Failure on Regular Hemodialysis

  2017cites this paper
• Profil diagnostique et évolutif du myélome multiple au Sénégal: étude monocentrique de 2005 à 2016

  2017cites this paper
• From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

  2017cites this paper
• Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials

  2017cites this paper
• [Diagnostic and evolutionary profile of multiple myeloma in Senegal: monocentric study conducted from 2005 to 2016].

  2017cites this paper
• Cardiopulmonary resuscitation in cancer patients: is there a problem?

  2017cites this paper
• New Methods in Treatment of Renal Failure in Patients with Multiple Myeloma : A Review with Immunological Approach

  2017cites this paper
• Disease and Symptom Care: A Focus on Specific Needs of Patients With Multiple Myeloma
.

  2017cites this paper
• Renal, GI, and Peripheral Nerves: Evidence‐based recommendations for the management of symptoms and care for patients with multiple myeloma

  2017cites this paper
• Myelosuppression, Bone Disease, and Acute Renal Failure: Evidence‐based recommendations for oncologic emergencies

  2017cites this paper
• Myeloma in the Real World: What Is Really Happening?

  2017cites this paper
• The Impact of Bortezomib in Renal Transplantation

  2016cites this paper
• Bortezomib‐based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis

  2016cites this paper
• High Cut Off Hemodialysis

  2016cites this paper
• The Impact of Bortezomib in Renal Transplantation

  2016cites this paper
• International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

  2016cites this paper
• Managing renal complications in multiple myeloma

  2016cites this paper
• Dysproteinemias and Kidney Disease

  2015cites this paper
• Handbook of Multiple Myeloma

  2015cites this paper
• Prognostic Significance of Initial Serum Albumin and 24 Hour Daily Protein Excretion before Treatment in Multiple Myeloma

  2015cites this paper
• Plasmapheresis in cast nephropathy: yes or no?

  2015cites this paper
• Treatment of elderly patients with myeloma

  2015cites this paper
• Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents.

  2014cites this paper
• Comment on: Think to prevent before than to treat renal impairment in multiple myeloma: do not forget tubular damage mimicking Fanconi syndrome

  2014cites this paper
• Not too little, not too much—just right! (Better ways to give high dose melphalan)

  2014cites this paper